Zenith Capital (Zenith Capital) Change In Receivables : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Change In Receivables?

Zenith Capital's change in receivables for the quarter that ended in . 20 was $0.00 Mil. It means Zenith Capital's Accounts Receivable stayed the same from . 20 to . 20 .

Zenith Capital's change in receivables for the fiscal year that ended in . 20 was $0.00 Mil. It means Zenith Capital's Accounts Receivable stayed the same from . 20 to . 20 .

Zenith Capital's Accounts Receivable for the quarter that ended in . 20 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zenith Capital's liquidation value for the three months ended in . 20 was $0.00 Mil.

Zenith Capital Change In Receivables Historical Data

The historical data trend for Zenith Capital's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Change In Receivables Chart

Zenith Capital Annual Data

Trend

Change In Receivables

Zenith Capital Quarterly Data

Change In Receivables

Zenith Capital Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zenith Capital (OTCPK:ZHCLF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zenith Capital's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Zenith Capital's accounts receivable are only considered to be worth 75% of book value:

Zenith Capital's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Zenith Capital Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines